Journal
TROPICAL MEDICINE AND INFECTIOUS DISEASE
Volume 4, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/tropicalmed4020089
Keywords
heme adduct; PfPI3KIII; artemisinin target
Categories
Funding
- NIH [2RO1AI056312-10, 1RO1AI111962-01]
Ask authors/readers for more resources
The molecular pharmacology of artemisinin (ART)-based antimalarial drugs is incompletely understood. Clinically, these drugs are used in combination with longer lasting partner drugs in several different artemisinin combination therapies (ACTs). ACTs are currently the standard of care against Plasmodium falciparum malaria across much of the world. A harbinger of emerging artemisinin resistance (ARTR), known as the delayed clearance phenotype (DCP), has been well documented in South East Asia (SEA) and is beginning to affect the efficacy of some ACTs. Though several genetic mutations have been associated with ARTR/DCP, a molecular mechanism remains elusive. This paper summarizes our current understanding of ART molecular pharmacology and hypotheses for ARTR/DCP.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available